ArticleCureus2025
A Case of a 12-cm Huge Hepatocellular Carcinoma Treated Successfully With Two-Stage CyberKnife Stereotactic Body Radiation Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Determining the optimal treatment for patients with huge hepatocellular carcinoma (HCC) remains challenging. Although surgical resection is the preferred option, it is feasible only in selected cases. Transarterial chemoembolization is commonly used but often provides insufficient local control. Advanced radiation therapy methods, such as real-time tumor tracking and inverse planning, have enabled the safe delivery of high-dose radiation via stereotactic body radiotherapy (SBRT), achieving excellent local control. However, alternative strategies may be necessary for difficult cases. We report the case of an 81-year-old male with a 12-cm unresectable HCC who was successfully treated with two-stage CyberKnife SBRT. Due to the tumor size and proximity to the gastrointestinal tract, single-stage SBRT was considered infeasible. The first-stage SBRT (25 Gy in three fractions, maximum dose of 55 Gy) induced tumor shrinkage, allowing for the second-stage SBRT (25 Gy in five fractions, maximum dose of 50 Gy) six months later. The only adverse event was transient radiation-induced fatigue two weeks post-treatment. A significant reduction in tumor volume was achieved, with no recurrence and preserved liver function for 44 months after initial treatment. This case highlights the potential of two-stage SBRT with real-time tumor tracking as an effective treatment strategy for unresectable huge HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.